IXICO
IXICO is a London-based imaging contract research organisation providing end-to-end neuroimaging services to biopharmaceutical companies conducting clinical trials in neurological diseases.
The company collects, manages, and analyses MRI, PET, and SPECT imaging data from global trial sites, generating AI-driven biomarker measurements used as clinical endpoints for eligibility, safety, and efficacy assessments.
Therapeutic focus areas include Alzheimer's, Huntington's, Parkinson's, and multiple sclerosis.
Latest News
IXICO Wins Two Alzheimer's Contracts Worth £1.5M
IXICO has won two Alzheimer's disease contracts worth about £1.5 million combined: neuroimaging analysis for a biotech's Phase 2b trial, and an extension supporting regulatory approval of a blood-based Alzheimer's diagnostic for a major diagnostics client.
IXICO Expects 28% Revenue Growth to £8.3M for FY26, Ahead of Guidance
IXICO expects FY26 revenue of £8.3 million, up 28% and ahead of its upgraded £8.0 million guidance, driven by a rise in analysis orders in the final quarter. The company ended the year with £10.4 million in cash and a £16.0 million order book, and expects its EBITDA loss to come in better than the £1.7 million guided.